Sold out · depth page
Tirzepatide — recent literature 2024–2026 (RUO)
Dual GIP / GLP-1 receptor agonist · LY3298176
Tirzepatide 10 mg · literature note
For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. Literature on this page is scientific context only. This page is not a licensed drug, a wellness protocol, or a dosing guide. This research material is not a licensed tirzepatide product.
This set keeps discovery, SURMOUNT-class, and islet (GIPR) citations that were title-checked. It does not fill the 2024–2026 mechanism gap with invented PMIDs.
Citation scope
PubMed is dense with 2024–2026 clinical-outcome and comparative papers that name tirzepatide. This research-use-only pack prioritizes discovery, receptor-pathway, and major controlled-trial identity papers already verified above.
Additional 2024–2026 primary dual-agonist mechanism or analytical papers (beyond the SURMOUNT-class and islet work) are not listed until each is verified against PubMed.
Yamanouchi (2025) is a class review of GIP and GLP-1, useful as a hub cross-link. It is not a compound-primary analytical paper for tirzepatide.
Identity
Form
Lyophilized powder, sealed vial
Strength
10 mg lyophilized vial
Purity
≥99% HPLC (see the lot COA when a lot returns)
CAS
- Tirzepatide: 2023788-19-2
PubMed
Selected literature
- PMID 30473097 (2018) Coskun et al., Molecular Metabolism — LY3298176 dual GIP/GLP-1 agonist discovery / proof of concept
- PMID 35658024 (2022) Jastreboff et al., NEJM — SURMOUNT-1 metabolic research publication
Recent literature (2023–2026)
- PMID 37385275 (2023) Garvey et al., Lancet — SURMOUNT-2 phase 3 research trial
- PMID 37277609 (2023) El et al., Nature Metabolism — tirzepatide / GIPR requirement in islet hormone-secretion research
- PMID 41515907 (2025) Yamanouchi, International Journal of Molecular Sciences — GIP and GLP-1 review (class context, not a compound-primary analytical paper)
Recent literature (2023–2026): Additional 2024–2026 primary dual-agonist mechanism or analytical papers (beyond the SURMOUNT-class and islet work) are not listed until each is verified against PubMed.
Literature is scientific context only. A paper does not make a research vial into a licensed medicine.
Bench reconstitution
Bench handling is on the companion note. This page is the literature set only. Reconstitute from the parent brief when a lot is in hand.
Diluent page: bacteriostatic water.
Storage
Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until the bench protocol calls for it. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook. Confirm the lot COA before you adopt a hold time.
Certificate of analysis
Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. This page is not a COA.
Lab FAQ
Why is the 2024–2026 mechanism list short?
Because only PubMed-verified papers are listed. Write request@pharmapeptidesrx.com to be notified when the 10 mg lot returns. This page does not publish prices or banking details. Invoices go out from request@ only.
In this library
Sold out
Notify on restock
This lot is sold out. Write request@pharmapeptidesrx.com and we email you when it is back.